Telaprevir is an investigational oral inhibitor of HCV protease, an enzyme essential for viral replication, and is being evaluated as part of a global Phase 3 registration program in more than 2,200 ...

The GS-441524 Remdesivir metabolite alongside ADP-ribose; HCV drug BOC binding to the NSP5 protease binding pocket. In the search for new ways to use small molecule drugs to prevent and treat Covid-19 ...

ABBOTT PARK, Ill., and WATERTOWN, Mass., Feb. 18, 2009 - Abbott and Enanta Pharmaceuticals announced today the advancement of their Hepatitis C (HCV) collaboration with a first-in-human study ...

Data from trials presented at the 2008 American Association for the Study of Liver Diseases (AASLD) meeting have highlighted the potential of an emerging class of drugs for hepatitis C virus (HCV) ...

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--MSD (NYSE: MRK), known as Merck in the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the ...

WHITEHOUSE STATION, N.J., May 14, 2011 /PRNewswire/ -- Merck (NYSE: MRK) (known as MSD outside the United States and Canada) announced today that the U.S. Food and Drug Administration (FDA) has ...

Hepatitis C viral loads dropped to undetectable levels in all patients receiving for about a month an investigational drug from Vertex Pharmaceuticals Inc. More specifically, the dozen treatment-na ve ...

Several advances afford promise for improving the management of hepatitis C virus (HCV) infection. Current therapies primarily target the immune system; the now proven ability to culture the entire ...

Patients who failed to achieve sustained virologic response after initial treatment for hepatitis C achieved high cure rates during retreatment after switching from an NS5A inhibitor direct-acting ...

If a patient tests positive for HCV, what type of treatment and support should physicians provide? It is important for physicians to explain that a positive HCV screening test requires additional ...

Antiviral drug development for COVID-19 took a back seat to vaccines during the brief time – when we thought that ending the pandemic was simply a matter of getting enough needles in enough arms. But ...

VICTRELIS is the first in a new class of medicines approved to treat chronic hepatitis C VICTRELIS is the first in a new class of medicines known as hepatitis C virus (HCV) protease inhibitors ...